CURE’s gynecologic cancer page is an extensive resource of cancer information featuring the latest gynecologic cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on gynecologic cancer.
October 21st 2024
Results from the RAMP 201 clinical trial are promising for patients with recurrent low-grade serous ovarian cancer.
FDA Approves Second Keytruda Indication for Subset of Advanced Endometrial Cancer
March 21st 2022The FDA’s approval of Keytruda is indicated for patients with advanced endometrial carcinoma with specific genetic characteristics whose disease progressed after systemic therapy and are not suitable for surgery or radiation.
FDA Approves Keytruda/Lenvima Combo for Advanced Endometrial Cancer
July 22nd 2021The Food and Drug Administration approved Keytruda plus Lenvima for patients with advanced endometrial carcinoma whose disease had progressed after previous systemic therapy and are not candidates for surgery or radiation.
FDA Grants Accelerated Approval to Jemperli for Endometrial Cancer
April 22nd 2021Jemperli (dostarlimab) received accelerated approval from the Food and Drug Administration for the treatment of patients with recurrent or advanced endometrial cancer whose disease has progressed on, or following, prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic biomarker known as deficient mismatch repair.